Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
David G. Standaert
University of Alabama at Birmingham, Department: Neurology
Should you be removed from our database? Contact us at [email protected]. Read more below.
ASTRAZENECA PHARMACEUTICALS LP
Payment for services (e.g., consulting fees, honoraria, paid authorship)
The outcome of the research is of significant business interest to the entity and therefore the financial interest could likely change based on the research results.
Genetic Susceptibility and Epigenetic Modulation in Levodopa Induced Dyskinesia
Parkinson's disease (PD) is a progressive neurodegenerative movement disorder that affects 3% of the population over age 65 and results in an economic cost to the United States of more than $25 billion dollars annually. Levodopa remains the most effective pharmacological therapy for PD but its use is limited by 'motor complications,' highlighted by dyskinesias. In this project, we will examine human genes that determine risk for levodopa-related dyskinesia, and fundamental mechanisms of memory involved in dyskinesia development providing important new approaches for the prevention and treatment of levodopa induced dyskinesia.
Filed on June 21, 2016.
Tell us what you know about David G. Standaert's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “David G. Standaert”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| David G. Standaert | University of Alabama at Birmingham | Conflict of Interest | SERINA THERAPEUTICS | $10,000 - $19,999 |
| David G. Standaert | University of Alabama at Birmingham | Conflict of Interest | ABBVIE, INC | $10,000 - $19,999 |
| David G. Standaert | University of Alabama at Birmingham | Conflict of Interest | ABBVIE, INC. | $10,000 - $19,999 |
| David G. Standaert | University of Alabama at Birmingham | Conflict of Interest | Serina Therapeutics | $5,000 - $9,999 |
| David G. Standaert | University of Alabama at Birmingham | Conflict of Interest | ABBVIE, INC | $0 - $4,999 |
| David G. Standaert | University of Alabama at Birmingham | Conflict of Interest | ABBVIE, INC | $0 - $4,999 |
| David G. Standaert | University of Alabama at Birmingham | Conflict of Interest | ASTRAZENECA PHARMACEUTICALS LP | $10,000 - $19,999 |
| David G. Standaert | University of Alabama at Birmingham | Conflict of Interest | ABBVIE, INC. | $0 - $4,999 |
| David G. Standaert | University of Alabama at Birmingham | Conflict of Interest | TEVA NEUROSCIENCE, INC. | $5,000 - $9,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.